Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiazinamium is a first-generation phenothiazine derivative with antihistaminic and anticholinergic properties. It acts primarily as an H1-antihistamine, interfering with the action of histamine at the Histamine H1 receptor to reduce inflammatory responses such as those seen in allergic rhinitis, conjunctivitis, and urticaria. Thiazinamium also exhibits anticholinergic effects due to its structural similarity to other phenothiazines. Its quaternary ammonium structure limits systemic absorption, making it suitable for topical use where systemic side effects are undesirable. The drug can stabilize mast cells and decrease pro-inflammatory cytokine expression by modulating intracellular signaling pathways[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiazinamium.